Recursion Pharmaceuticals, Inc.
RXRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001601830
In the last 90 days, Recursion Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 4 sales; 344 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $435.0K in total
- 4
- 13F holdersQ2 2026, +12 vs. previous quarter
- 344
- 13F valueReported value at the end of Q2 2026
- $1.33B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding RXRX, Q2 2026
1 superinvestor reports holding Recursion Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
ARK Invest
Cathie Wood
1.0%
Recursion Pharmaceuticals, Inc.'s share of the portfolio
- Shares
- 41,337,632
- Value
- $151.7M
Latest insider trades
Open-market purchases and sales by Recursion Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)5:55 PM ET | Sep 8 | 2 days | Khan NajatCEO and President | SSaleClass A Common Stock | −22.4K | $3.52 | −$78.8K | −1.1%2.07M after | 10b5-1 |
| Sep 2, 2026 (view filing)6:01 PM ET | Sep 1 | 1 day | Borgeson BlakeDirector | SSaleClass A Common Stock | −30.0K | $3.34 | −$100.2K | −0.5%6.16M after | 10b5-1 |
| Aug 6, 2026 (view filing)5:09 PM ET | Aug 4 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −30.0K | $3.25 | −$97.5K | −0.5%6.19M after | 10b5-1 |
| Jul 9, 2026 (view filing)6:04 PM ET | Jul 7 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −40.0K | $3.96 | −$158.5K | −0.6%6.22M after | 10b5-1 |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Bumpus NamandjeDirector | SSaleClass A Common Stock | −3.96K | $3.18 | −$12.6K | −3.0%127.6K after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 5 | Same day | Khan NajatCEO and President | SSaleClass A Common Stock | −23.6K | $3.58 | −$84.4K | −1.1%2.18M after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 5 | Same day | Gibson ChristopherDirector | SSaleClass A Common Stock | −40.0K | $3.62 | −$144.8K | −4.3%883.7K after | 10b5-1 |
| Jun 4, 2026 (view filing) | Jun 3 | 1 day | Bumpus NamandjeDirector | SSaleClass A Common Stock | −4.39K | $3.54 | −$15.5K | −9.2%43.2K after | 10b5-1 |
| Jun 4, 2026 (view filing) | Jun 2 | 2 days | Borgeson BlakeDirector | SSaleClass A Common Stock | −30.0K | $3.68 | −$110.4K | −0.5%6.17M after | 10b5-1 |
| May 27, 2026 (view filing) | May 22 | 5 days | Gibson ChristopherDirector | SSaleClass A Common Stock | −40.0K | $3.08 | −$123.2K | −4.3%883.7K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Recursion Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 50,304,691 | $184.6M | 0.00% | +7,112,385+16.5% | Added |
| ARK Investment Management LLCSuperinvestorARK Invest | 41,337,632 | $151.7M | 0.98% | +1,124,863+2.8% | Added |
| State Street Corp | 34,706,130 | $127.4M | 0.00% | +6,215,492+21.8% | Added |
| Vanguard Portfolio Management LLC | 31,131,599 | $114.3M | 0.01% | +8,372,499+36.8% | Added |
| Baillie Gifford & Co | 23,487,907 | $86.2M | 0.08% | −187,500−0.8% | Reduced |
| Vanguard Capital Management LLC | 22,765,940 | $83.6M | 0.00% | +521,553+2.3% | Added |
| Geode Capital Management, LLC | 13,819,135 | $50.7M | 0.00% | +1,544,051+12.6% | Added |
| Softbank Group Corp | 13,636,515 | $50.0M | 0.28% | 00.0% | Unchanged |
| MIC Capital Management UK LLP | 9,644,033 | $35.4M | 8.98% | +10.0% | Added |
| UBS Group AG | 8,947,102 | $32.8M | 0.01% | +3,845,865+75.4% | Added |